ASLAN Pharmaceuticals Announces Acceptance of Abstracts on New Varlitinib Data in BTC at ASCO Gastrointestinal Cancers Symposium
November 27, 2018 04:47 ET
|
ASLAN Pharmaceuticals Limited
SINGAPORE, Nov. 27, 2018 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (NASDAQ:ASLN, TPEx:6497), a clinical-stage biopharmaceutical company targeting cancers that are both highly prevalent in Asia and...
Aslan Pharmaceuticals to Participate in 30th Annual Piper Jaffray Healthcare Conference
November 20, 2018 05:00 ET
|
ASLAN Pharmaceuticals Limited
SINGAPORE, Nov. 20, 2018 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (NASDAQ:ASLN, TPEx:6497), a clinical-stage biopharmaceutical company targeting cancers that are both highly prevalent in Asia and...
ASLAN Pharmaceuticals Reports Third Quarter 2018 Financial Results and Provides Corporate Update
November 08, 2018 06:05 ET
|
ASLAN Pharmaceuticals Limited
SINGAPORE, Nov. 08, 2018 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (NASDAQ:ASLN, TPEx:6497), a clinical-stage biopharmaceutical company targeting cancers that are both highly prevalent in Asia and...
ASLAN Pharmaceuticals to Present New Data on ASLAN003 at American Society of Hematology Annual Meeting
November 01, 2018 10:20 ET
|
ASLAN Pharmaceuticals Limited
SINGAPORE, Nov. 01, 2018 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (NASDAQ:ASLN, TPEx:6497), a clinical-stage biopharmaceutical company targeting cancers that are both highly prevalent in Asia and...
ASLAN Pharmaceuticals Appoints Robert E. Hoffman as Independent Director
October 30, 2018 03:54 ET
|
ASLAN Pharmaceuticals Limited
SINGAPORE, Oct. 30, 2018 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (NASDAQ:ASLN, TPEx:6497), a clinical-stage biopharmaceutical company targeting cancers that are both highly prevalent in Asia and...
New Data Presented on ASLAN’s varlitinib at ESMO Show Promising Results in Heavily Pre-Treated BTC and CRC Patients
October 22, 2018 07:00 ET
|
ASLAN Pharmaceuticals Limited
SINGAPORE, Oct. 22, 2018 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (NASDAQ:ASLN, TPEx:6497), a clinical-stage biopharmaceutical company targeting cancers that are both highly prevalent in Asia and...
ASLAN Pharmaceuticals Enrolls First Subject in Phase 1 Study for ASLAN004 in Atopic Dermatitis
October 17, 2018 12:31 ET
|
ASLAN Pharmaceuticals Limited
SINGAPORE, Oct. 18, 2018 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (ASLAN, 6497.TT, Nasdaq: ASLN), a clinical-stage biopharmaceutical company targeting cancers that are both highly prevalent in Asia...
ASLAN Pharmaceuticals to Present Posters on Varlitinib and ASLAN003 at European Society for Medical Oncology Congress
October 09, 2018 06:15 ET
|
ASLAN Pharmaceuticals Limited
SINGAPORE, Oct. 09, 2018 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (ASLAN, 6497.TT, Nasdaq: ASLN), a clinical-stage biopharmaceutical company targeting cancers that are both highly prevalent in Asia...
ASLAN Pharmaceuticals Presents Two Posters on Varlitinib at Chinese Society of Clinical Oncology Annual Meeting
September 21, 2018 04:00 ET
|
ASLAN Pharmaceuticals Limited
SINGAPORE, Sept. 21, 2018 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (NASDAQ:ASLN, TPEx:6497), a clinical-stage biopharmaceutical company targeting cancers that are both highly prevalent in Asia and...
ASLAN Pharmaceuticals Provides Update on Timelines for Clinical Trial of Varlitinib in Biliary Tract Cancer in China
September 17, 2018 06:58 ET
|
ASLAN Pharmaceuticals Limited
SINGAPORE, Sept. 17, 2018 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (NASDAQ:ASLN, TPEx:6497), a clinical-stage biopharmaceutical company targeting cancers that are both highly prevalent in Asia and...